Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These gastrointestinal adverse events are poorly documented in the literature due to their low frequency [6].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose‐dependent relationship [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [66]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global clinical measure of fitness and frailty in elderly people
Rockwood, K. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050051 · Cited by 8,968 · cited 1×
“The Clinical Frailty Scale may sometimes be useful to guide dose adjustment [75].”
MethodLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“CKD increases the risk of GLP-1 RA-associated diarrhoea, with symptoms being more severe with albuminuria [84].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
BackgroundResultSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney di…”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
Background
Research works printed but not linked: 2
- 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
- 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501006 · Cited by 416
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation; and tend to decrease in frequency and severity with continuation of a stable dose [38].”
InfluentialNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
“Although the data is limited, it is important to highlight that there are certain interventions that can be considered to minimize the incidence and intensity of side effects [36].”
BackgroundJi, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44067-4 · Cited by 118
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 192
The emergence of obesity in type 1 diabetes
Kueh, M. T. W., Chew, N. W. S., Al-Ozairi, E., & le Roux, C. W. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01429-8 · Cited by 111
“2), [49, 117, 122, 123] a tantalizing opportunity arises to forge novel pathways in the harmonisation of treatment strategies.”
BackgroundBerg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
“42 This contributed to similar adherence rates between oral semaglutide, sub-cutaneous semaglutide, and liraglutide in the PIONEER and SUSTAIN trials.”
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
“Moreover, liraglutide, orforglipron, semaglutide, and tirzepatide also increased the risk of vomiting, while cagrilinitide and exenatide did not.”
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“This can be managed by initiating at a lower dose, followed by slow dose escalation and using antiemetics when required [20, 83].”
BackgroundExploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“To reduce these potential risks, healthcare providers are advised to closely monitor patients, particularly those with a history of gallbladder or biliary disease [49].”
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1566498 · Cited by 64
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“…low fiber foods, reduce consumption of dairy, coffee, alcohol [156] Constipation Encourage physical activity, hydration, ample fiber in diet [156] Pancreatitis Discontinue drug, standard treatment for pancreatitis [156] Alopecia Change to a different GLP-1 medication, topical hair loss…”
InfluentialSztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
BackgroundDesai, A., Petrov, J. C., Hashash, J. G., Patel, H. D., Brahmbhatt, B. S., Kochhar, G. S., & Farraye, F. A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18138 · Cited by 47
“26 Recent studies have also raised concerns regarding the potential for more serious GI side effects like pancreatitis, bowel obstruction and gastroparesis in patients on semaglutide.”
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications
Burke, O. M., Sa, B., Cespedes, D. A., & Tosti, A. (2025) · Skin Appendage Disorders · doi:10.1159/000544023 · Cited by 55
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
“95,96 Medication adjustments are recommended only when symptoms do not resolve.”
Health Benefits Beyond the Scale: The Role of Diet and Nutrition During Weight Loss Programmes
Contreras, F., Al‐Najim, W., & le Roux, C. W. (2024) · Nutrients · doi:10.3390/nu16213585 · Cited by 48
Nakhla, M., Nair, A. V., Balani, P., Ujjawal, A., Kumar, P. A., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07613-w · Cited by 49
“These symptoms affect approximately 5–20% of individuals undergoing treat-ment for diabetes or obesity, with up to 12% discontinuing the medication due to undesirable upper gastrointestinal side effects [28].”
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s494919 · Cited by 32
“8 In this regard, a group of medical experts, including endocrinologists, nephrologists, general practitioners, cardiologists, internal medicine specialists, and nurses, recently have developed dietary and behavioral guidelines to prevent or minimize gastrointestinal effects and avoid medication…”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Sasaki, T., Giang, S. M.-L., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, Y. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf193 · Cited by 41
“However, gastrointestinal side effects, a well-reported limitation of GLP1-RAs [28 ], were more common.”
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“In support of these findings, a multidisciplinary expert panel reviewing available literature concluded that 40–70% of patients experience GI side effects while on GLP-1RA therapy, with most cases being transient and self-limiting [103].”
InfluentialSievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 58
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
“Close monitoring and discontinuation of medication may be necessary in cases of acute worsening of kidney function [ 35, 36].”
Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis
Park, S., Jain, R., & Mirfakhraee, S. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.08.005 · Cited by 26
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“Small meals should be consumed slowly with adequate fluids, and temporary lowering of dose or temporary suspension of therapy should be considered if GI adverse effects do not remit [34].”
BackgroundHow ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“Some studies have indicated increase hair loss associated with the use of GLP-1RAs such as semaglutide, while others found that the clinical evidence linking GLP-1 agonists to hair loss remains sparse and inconclusive, warranting further investigation (Desai et al., 2024; Godfrey et al., 2025).”
InfluentialMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Abdulhameed, N., Babin, A., Hansen, K. M., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01537-1 · Cited by 27
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 31
“GLP-1 RAs and GLP/GIP agonists may cause gastrointestinal disturbances, which may impact tolerability; however, these mostly occur during dose escalation, usually fade with time and are typically mild to moderate in severity [45].”
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
The antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024) · Diabetes Care · doi:10.2337/dc23-1791 · Cited by 22
Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coşkun, T., Long, A., Allen, D., O’Farrell, L. S., Bowen, B., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102271 · Cited by 26
“In populations being treated for weight management, incretin class medications are well recognized to produce gastrointestinal adverse events [29,30].”
The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study
Long, J. J., Sahi, S. S., Lemke, A. I., Na, J., Valencia, O. A. G., Budhiraja, P., Wadei, H. M., Sudhindran, V., Benzo, R., Clark, M. M., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.07.008 · Cited by 22
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 23
Abdulraheem, A., Abujaber, B. A., Ayers, L., Zureikat, Q. A., Bashiri, K., Almhanni, G., Altork, N. A., Afzal, U., Qarkash, D., Spyros, P., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11962-4 · Cited by 23
Despain, D., & Hoffman, B. L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100143 · Cited by 19
“However, the successful implementation of GLP-1 RA therapy is not without challenges; these include gastrointestinal adverse events (GI AEs), potential risks of undernutrition, loss of lean body mass, and the propensity for weight regain after treatment cessation [6 – 9].”
BackgroundResultEffect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 37
“[126] Although GLP-1 RAs have a low hypoglycemia risk, it is crucial to educate patients about symptom recognition, particularly if they are using other glucose-lowering medications.”
BackgroundEmbracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
Moyad, M. A. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01180-7 · Cited by 21
Chowdhury, S. R., Sadouki, F., Collins, E., Keen, F., Bhagi, R., Lim, Y. S. J., Cozma, S. L., & Bain, S. C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01551-4 · Cited by 19
“Healthcare providers may also slow or halt dose escalation in response to emerging side effects [22].”
Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Kawashima, J., Mumtaz, K., & Pawlik, T. M. (2025) · World Journal of Surgery · doi:10.1002/wjs.12484 · Cited by 21
“particularly gastrointestinal issues such as delayed gastric emptying [5].”
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Brosnihan, P., Luce, M. S., Yetasook, A. K., Perez, C., Scharf, K. R., & Aly, S. (2025) · The American Surgeon™ · doi:10.1177/00031348251337145 · Cited by 17
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“Common adverse effects include nausea, diarrhoea and constipation [41].”
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 19
“According to data issued from clinical trial programs, transient interruption of GLP-1 RA treatment has been reported to occur in up to 12% of treated patients (vs. ~2% with placebo), with permanent discontinuations ranging between 1.6% and 6% of treated patients (vs. 1% with placebo) [63,65,66].”
BackgroundMethodInfluentialKhan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
“However, the side effects are transient with mild to moderate severity and both Liraglutide and Semaglutide are well-tolerated by patients particularly, once the maintenance dose is reached [79,80].”
Barrientos-Ávalos, J. R., Morel-Cerda, E. C., Téllez, F. A. F., Vidrio-Huerta, B. E., Aceves-Ayala, A. R., Flores-Rendón, Á. R., & Velasco, J. A. V.-R. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.10.008 · Cited by 32
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
“…crucial to minimize the occurrence and/or the severity of the most common gastrointestinal side effects of GLP-1 RA, as it has recently been published by an expert panel including endocrinologists, nephrologists, primary care physicians, internists, cardiologists and diabetes nurse educators [215].”
Kaplan, L. M., Startseva, E., le Roux, C. W., Wharton, S., Bozkurt, B., Mazo, D. F. D. C., von Schlippenbach, J., Maldonado, S. G., Hussain, S. A., Neff, G. W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04479-3 · Cited by 29
“…dose-escalation protocol underscores the importance of individualized dose management during the early phase of treatment to achieve optimal therapeutic benefit, the approach most commonly taken with other medications containing GLP-1R agonist activity in real-world clinical practice 46–48 .”
Coppin, G., Tord, D. M., Pool, E. R., Locatelli, L., Achaïbou, A., Erdemli, A., Pérez, L. L., Wuensch, L., Cereghetti, D. M., Golay, A., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01370-w · Cited by 18
“The fi rst and most obvious hypothesis is that GLP-1 agonist-related side effects (e.g., nausea, vomiting) are responsible for a decrease in appetite and weight reduction; however, most treated patients lose weight in the absence of clinically signi fi cant side effects [7, 8].”
Obesity – Standards, trends and advances
Gołacki, J., & Matyjaszek‐Matuszek, B. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.001 · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Most common AEs include mild-moderate gastrointestinal events ( nausea, vomiting, constipation, and diarrhea) that are typically transient and could be limited by gradual up-titration over weeks [115 , 134 , 135 ].”
Katzman, J. L., Haider, M. A., Cardillo, C., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.02.042 · Cited by 19
Noh, Y., Yin, H., Yu, O. H. Y., Bitton, A., & Azoulay, L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03420 · Cited by 18
Saha, B., Kamalumpundi, V., & Codipilly, D. C. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.09.017 · Cited by 26
Wiener, B. G., Gnirke, M., Vassallo, S. U., Smith, S. W., & Su, M. K. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2322049 · Cited by 17
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Yang, Y., Liu, W., Zhang, Z., zhang, Y., Wang, X., Wang, J., Cai, H., Liu, Y., Meng, R., Fu, Y., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103414 · Cited by 19
Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155531 · Cited by 16
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“5] [27,47,99,128,129].”
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
“70,72”
InfluentialYuan, J., Liu, W., Jiang, X., Huang, Y., Zong, L., Ding, H., Shen, X., Sun, Y., Feng, X., Li, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66998-8 · Cited by 19
Riedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 17
Johnson, B. V. B., Milstead, M., Kreider, R., & Jones, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100209 · Cited by 27
Hoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 21
“104,107 Other references considered that GLP-1RAs were more likely to cause nausea and headache than metformin.”
Swift, D. L., Ross, L. M., Laddu, D. R., Conroy, M. B., German, C. A., Evangelista, L. S., Marvel, F. A., Jerome, G. J., on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health, Council on Cardiovascular and Stroke Nursing, et al. (2026) · Circulation · doi:10.1161/cir.0000000000001441 · Cited by 13
Zhang, J., Wang, X., & Zhou, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1471615 · Cited by 17
Gameil, M. A., Yousef, E. A. A. M., Marzouk, R. E., Emara, M., Abdelkader, A. H., & Salama, R. I. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01526-2 · Cited by 16
“Hence, the risk of cholelithiasis should be considered and addressed in patients treated with GLP-1RAs [11].”
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“Achievement of sus - tained results often requires a multidisciplinary approach, with close collaboration among healthcare professionals to deliver coordinated, patient-centred care that effectively integrates pharmacological treatment and nutritional strategies for balanced weight loss [15, 26 ].”
InfluentialLambert, F., Guillon, E., Gatta‐Cherifi, B., CranioGLP1_FORCE Group, Soula, H., Poitou, C., & Faucher, P. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70216 · Cited by 12
“29 In patients with adrenal insufficiency, digestive symptoms may be misattributed to GLP-1 RAs, leading to premature discontinuation.”
Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement
Castellanos, V., Workneh, H. T., Malik, A. I., & Mehta, B. K. (2024) · Cureus · doi:10.7759/cureus.55324 · Cited by 12
“Given its recent introduction to the market, specific reports of autoimmune reactions and related side effects have not been extensively studied yet [11,12].”
BackgroundKaur, U., Pathak, B. K., Meerashahib, T. J., Krishna, D. V. V., & Chakrabarti, S. S. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01351-5 · Cited by 15
Weng, J., Alizadeh, M. A., & Friedman, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09344-w · Cited by 15
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 21
“Gradual dose titration of GLP-1 therapies can also improve tolerability, typically involving dose escalation every 4 weeks or longer, with temporary maintenance or dose reduction when adverse effects occur [34,35].”
InfluentialShariat‐Madar, Z., & Mahdi, F. (2025) · Molecules · doi:10.3390/molecules30224448 · Cited by 18
Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 16
“Evidence shows that combining GLP-1RAs with probiotics, prebiotics and targeted dietary modifications improves glycae - mic outcomes and may rescue treatment responsiveness in patients with poor initial response [ 82].”
Rosenstock, J., Billings, L. K., Gajria, R., Giorgino, F., Johansen, N. B., Klein, K. R., Thamattoor, U. K., Buse, J. B., & Jain, A. B. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01022-6 · Cited by 15
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
“Gastrointestinal AEs are common with this class of medication, as they are with all GLP-1R agonists [97].”
BackgroundMethodWANG, Q., Cui, Q., Xu, Y., Prud’homme, G. J., Yang, Y., Zhu, D., Li, Y., Yang, Y., & Li, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16452 · Cited by 12
“23 No drug-related hypoglycaemic events were observed.”
BALDASSARRE, M. P. A., Dalmazi, G. D., Coluzzi, S., Carrieri, F., Febo, F., Centorame, G., Cassino, P., Piacentino, L., Baroni, M. G., Consoli, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113054 · Cited by 13
“Thus, reinforcing dietary advice (e.g., prefer low-fat foods, eat meals slowly and only if actually hungry, consume smaller portions, stop eating in case of feeling of fullness) [27] is extremely necessary in people receiving semaglutide oral formulation.”
BackgroundLiraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 12
Jevnikar, B. E., Ramos, M. S., Pasqualini, I., Khan, S. T., & Piuzzi, N. S. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2444408 · Cited by 10
“Additionally, individualized care using point-of-care ultrasound may be needed to manage complications associated with GLP-1 agonists, including gastroparesis and pulmonary aspiration [60–62].”
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
Gravina, A. G., Pellegrino, R., Izzo, M., Costanzo, I. D., Imperio, G., Landa, F., Tambaro, A., & Federico, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050383 · Cited by 10
“Despite their potential benefits to the disease course, careful attention should be given when GLP-1 RAs are used in IBD patients since their most common side effects involve the gastrointestinal tract, with nausea, vomiting, diarrhoea, and constipation being the most frequently reported [62,63].”
Minnetti, M., Barazzoni, R., Batsis, J. A., Busetto, L., Yumuk, V., Poggiogalle, E., Weijs, P. J. M., & Donini, L. M. (2025) · Obesity Facts · doi:10.1159/000548370 · Cited by 15
“A multidisciplinary consensus has outlined practical recommendations to improve drug tolerability, including eating slowly, consuming smaller portions, avoiding sweet meals, and choosing easy-to-digest, low-fat foods such as bland diets [66].”
Metadata
- Authors
- Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
- Affiliations
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
- Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
- Hospital Universitario La Paz (ES)
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
- Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Madrid Health Service (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Universitat de València (ES)
- Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-12-24
- Volume
- 12
- Issue
- 1
- Pages
- 145
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821052
- OpenAlex
- W4313260808
- Cited by
- 358
- References
- 83
- Citations by year
- 2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
- FWCI
- 40.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo-Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.